Last reviewed · How we verify
Life-Threatening Ventricular Tachycardia
Approved treatments
- Bretylium Tosylate · Pfizer
- Cordarone · Pfizer
Amiodarone, a class III antiarrhythmic, blocks sodium, potassium, and calcium channels, prolongs cardiac action potentials, and has vasodilatory effects. - Quinidine Gluconate · Eli Lilly
Quinidine Gluconate works by blocking the M2 muscarinic acetylcholine receptor, which helps regulate heart rhythm. - Tambocor
- Betapace · Bayer
- Isocain · Pfizer
- Inderal · Generic (originally ICI/AstraZeneca)
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Life-Threatening Ventricular Tachycardia patent landscape — cliff calendar, originator estates, attackable patents
- Life-Threatening Ventricular Tachycardia treatment landscape brief
- Life-Threatening Ventricular Tachycardia treatment updates RSS
Frequently asked questions about Life-Threatening Ventricular Tachycardia
What drugs treat Life-Threatening Ventricular Tachycardia?
Tracked treatments include Bretylium Tosylate, Cordarone, Quinidine Gluconate, Tambocor, Betapace, Isocain, Inderal.
What is the treatment for Life-Threatening Ventricular Tachycardia?
Standard treatment for Life-Threatening Ventricular Tachycardia includes Bretylium Tosylate, Cordarone, Quinidine Gluconate, Tambocor, Betapace. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Life-Threatening Ventricular Tachycardia patent cliff · Life-Threatening Ventricular Tachycardia CI report
- Treatment: Bretylium Tosylate · Pfizer
- Treatment: Cordarone · Pfizer
- Treatment: Quinidine Gluconate · Eli Lilly
- Treatment: Tambocor
- Treatment: Betapace · Bayer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing